CI

At a glance

ClinicalIndex Comparison Record
Phase 3Completed· 862 enrolled
Drug / intervention
Galcanezumab +1 moredrug
Likely dose
Galcanezumab administered subcutaneouslyAI-extracted
Key inclusion· 4
  • ✓Diagnosis of episodic migraine per IHS ICHD-3 beta (types 1.1 or 1.2)
  • ✓At least 1 year of migraine history prior to screening
  • ✓Migraine onset before age 50
  • ✓4–14 migraine headache days per month (monthly frequency)
Key exclusion· 4
  • ✕Current use or prior exposure to galcanezumab or any other CGRP antibody
  • ✕Known hypersensitivity to monoclonal antibodies, therapeutic proteins, or galcanezumab
  • ✕History of persistent daily headache or cluster headache
  • ✕Hemiplegic migraine (sporadic or familial), ophthalmoplegic migraine, or basilar-type migraine

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02614183
NCT02614183Phase 3Completed
CompareCT.gov

A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of LY2951742 in Patients With Episodic Migraine - the EVOLVE-1 Study

Eli Lilly and Company·interventional·Posted Nov 25, 2015·Updated Jun 17, 2020

In Brief

A Phase 3 clinical trial evaluating Galcanezumab and Placebo for Migraine. Completed, enrolled 862 participants across 95 sites in 3 countries.

Detailed Summary

The main purpose of this study is to evaluate the efficacy of the study drug known as galcanezumab in participants with episodic migraine.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsMigraine
CountriesCanada, Puerto Rico, United States
Collaborators--

Timeline

Phase 3CompletedFinished
20162017201820192020202120222023202420252026
First PostedNov 25, 2015
Enrollment StartNov 30, 2015
Primary CompletionMar 22, 2017
Study CompletionAug 9, 2018
TodayJul 2, 2026
Enrollment to primary: 1.3 yearsPosted 10.6 years ago

Interventions

Galcanezumabdrug

Administered SC

Placebodrug

Administered SC